<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108038</url>
  </required_header>
  <id_info>
    <org_study_id>A105_02PK2115</org_study_id>
    <nct_id>NCT05108038</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Crossover Phase 1 Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety After Single/Multiple Administration of CKD-382, D860 and D027 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate the pharmacokinetics, pharmacodynamics and safety after single/multiple&#xD;
      administration of CKD-382, D860 and D027 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, crossover phase 1 clinical trial to evaluate the pharmacokinetics,&#xD;
      pharmacodynamics and safety after single/multiple administration of CKD-382, D860 and D027 in&#xD;
      healthy subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>AUCt,ss Evaluation after multiple dose&#xD;
-AUCt,ss: Area under the plasma drug concentration-time curve within a dosing interval in steady-state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Pharmacodynamic Endpoint</measure>
    <time_frame>24 hours after multiple dose for 7 days compared to baseline</time_frame>
    <description>Percent decrease from baseline in integrated gastric acidity for 24-hour interval after 7th dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Cmax,ss Evaluation after multiple dose&#xD;
-Cmax,ss: Maximum concentration of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Tmax,ss Evaluation after multiple dose&#xD;
-Tmax,ss: Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>t1/2ss Evaluation after multiple dose&#xD;
-t1/ss: Terminal elimination half life in steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>CLss/F Evaluation after multiple dose&#xD;
-CLss/F: Apparent Clearance in steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Vzss/F Evaluation after multiple dose&#xD;
-Vzss/F: Apparent Volume of Distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>R Evaluation after multiple dose&#xD;
-R: Accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>PTF Evaluation after multiple dose&#xD;
-PTF: Peak to Trough Fluctuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Cmax Evaluation after single dose&#xD;
-Cmax: Maximum concentration of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>AUC0-t Evaluation after single dose&#xD;
-AUC0-t: Area under the plasma concentration-time curve from the point of administration to last time point of blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Tmax Evaluation after single dose&#xD;
-Tmax: Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>t1/2 Evaluation after single dose&#xD;
-t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>CL/F Evaluation after single dose&#xD;
-CL/F: Apparent Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacokinetic Endpoint</measure>
    <time_frame>0 hour(pre dose), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Vz/F Evaluation after single dose&#xD;
-Vz/F: Apparent Volume of Distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(1) Secondary Pharmacodynamic Endpoint</measure>
    <time_frame>24 hours after first dose compared to baseline</time_frame>
    <description>Percent decrease from baseline in integrated gastric acidity for 24-hour interval after first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(2) Secondary Pharmacodynamic Endpoint</measure>
    <time_frame>24 hours after first dose and multiple dose for 7 days</time_frame>
    <description>Percent of time with gastric pHâ‰¤4 for 24-hour interval after first or 7th dose</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-382 Period 2: D860 Period 3: D027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-382 Period 2: D027 Period 3: D860</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D860 Period 2: D027 Period 3: CKD-382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D860 Period 2: CKD-382 Period 3: D027</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D027 Period 2: D860 Period 3: CKD-382</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D027 Period 2: CKD-382 Period 3: D860</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-382, D860, D027</intervention_name>
    <description>QD, PO for 7days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 19 aged and 50 aged in healthy adult&#xD;
&#xD;
          -  Body weight more than 50kg&#xD;
&#xD;
          -  BMI more than 18.0 and under 27.0&#xD;
&#xD;
          -  Who has negative result on Helicobacter Pylori antibody test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have clinically significant disease that hepatobiliary system, kidney, nervous system,&#xD;
             immune system, respiratory system, endocrine system, hemato-oncology disease,&#xD;
             cardiovascular system or mental illness, or a history of mental disease&#xD;
&#xD;
          -  Have a gastrointestinal disease history(including surgery) that can effect drug&#xD;
             absorption&#xD;
&#xD;
          -  Hypersensitivity reaction of clinically significant hypersensitivity reaction in the&#xD;
             history of Esomeprazole, additives or benzimidazole family&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minkyu Park, Ph.D</last_name>
    <phone>043-269-8708</phone>
    <email>mk_park@cbnuhctc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungbuk Ntional University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minkyu Park, Ph.D</last_name>
      <phone>043-269-8708</phone>
      <email>mk_park@chnuhctc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-382</keyword>
  <keyword>D860</keyword>
  <keyword>D027</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

